These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35875887)

  • 1. Targeting the Receptor-Binding Motif of SARS-CoV-2 with D-Peptides Mimicking the ACE2 Binding Helix: Lessons for Inhibiting Omicron and Future Variants of Concern.
    Valiente PA; Nim S; Lee J; Kim S; Kim PM
    J Chem Inf Model; 2022 Aug; 62(15):3618-3626. PubMed ID: 35875887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Potential ACE2-Derived Peptide Mimetics in SARS-CoV-2 Omicron Variant Therapeutics using Computational Approaches.
    Paul S; Nadendla S; Sobhia ME
    J Phys Chem Lett; 2022 Aug; 13(32):7420-7428. PubMed ID: 35929665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Design and Experimental Validation of ACE2-Derived Peptides as SARS-CoV-2 Receptor Binding Domain Inhibitors.
    Sarma S; Herrera SM; Xiao X; Hudalla GA; Hall CK
    J Phys Chem B; 2022 Oct; 126(41):8129-8139. PubMed ID: 36219223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equine Anti-SARS-CoV-2 Serum (ECIG) Binds to Mutated RBDs and N Proteins of Variants of Concern and Inhibits the Binding of RBDs to ACE-2 Receptor.
    Andrade SA; Batalha-Carvalho JV; Curi R; Wen FH; Covas DT; Chudzinski-Tavassi AM; Moro AM
    Front Immunol; 2022; 13():871874. PubMed ID: 35898497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omicron: A Heavily Mutated SARS-CoV-2 Variant Exhibits Stronger Binding to ACE2 and Potently Escapes Approved COVID-19 Therapeutic Antibodies.
    Shah M; Woo HG
    Front Immunol; 2021; 12():830527. PubMed ID: 35140714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility.
    Boer JC; Pan Q; Holien JK; Nguyen TB; Ascher DB; Plebanski M
    Front Immunol; 2022; 13():954435. PubMed ID: 36569921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the binding capacity of lactic acid bacteria derived bacteriocins against RBD of SARS-CoV-2 Omicron variant by molecular simulations.
    Erol I; Kotil SE; Ortakci F; Durdagi S
    J Biomol Struct Dyn; 2023 Dec; 41(20):10774-10784. PubMed ID: 36591650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Potential Peptide-Based Inhibitors against SARS-CoV-2 and Variants of Concern.
    Boshah H; Samkari F; Valle-Pérez AU; Alsawaf SM; Aldoukhi AH; Bilalis P; Alshehri SA; Susapto HH; Hauser CAE
    Biomed Res Int; 2023; 2023():3892370. PubMed ID: 37869628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies.
    Reuter N; Chen X; Kropff B; Peter AS; Britt WJ; Mach M; Überla K; Thomas M
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational studies on the interaction of SARS-CoV-2 Omicron SGp RBD with human receptor ACE2, limonin and glycyrrhizic acid.
    Vardhan S; Sahoo SK
    Comput Biol Med; 2022 May; 144():105367. PubMed ID: 35247766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Fc-binding profiles and ACE2 affinity to SARS-CoV-2 RBD variants.
    Haycroft ER; Davis SK; Ramanathan P; Lopez E; Purcell RA; Tan LL; Pymm P; Wines BD; Hogarth PM; Wheatley AK; Juno JA; Redmond SJ; Gherardin NA; Godfrey DI; Tham WH; Selva KJ; Kent SJ; Chung AW
    Med Microbiol Immunol; 2023 Aug; 212(4):291-305. PubMed ID: 37477828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor binding domain of SARS-CoV-2 from Wuhan strain to Omicron B.1.1.529 attributes increased affinity to variable structures of human ACE2.
    Patil S; Alzahrani KJ; Banjer HJ; Halawani IF; Alzahrani H; Altayar MA; Albogami S; Angeles RF; Hassan AAA; Bhandi S; Raj AT
    J Infect Public Health; 2022 Jul; 15(7):781-787. PubMed ID: 35738053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor.
    Treewattanawong W; Sitthiyotha T; Chunsrivirot S
    Sci Rep; 2023 Sep; 13(1):15476. PubMed ID: 37726329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
    Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
    Front Immunol; 2021; 12():691715. PubMed ID: 34149735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the transmission feasibility of SARS-CoV-2 Omicron (B.1.1.529) variant to 143 mammalian hosts: insights from S protein RBD and host ACE2 interaction studies.
    Samanta A; Alam SSM; Ali S; Hoque M
    Funct Integr Genomics; 2023 Jan; 23(1):36. PubMed ID: 36631570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.